Iovance Biotherapeutics, Inc.
Every calculator, already run for IOVA
Open the full toolkit →You have the numbers on IOVA. Get the argument.
A written report on which of these readings actually decide the outcome for Iovance Biotherapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
10 analysts covering IOVAAnalyst Price Target Disagreement for Iovance Biotherapeutics, Inc.
Wall Street's bull case implies +43% from the current price; the bear case implies -50%. A 93% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for IOVA
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cel…
IOVA — frequently asked
Is IOVA a buy right now?
Wall Street's consensus rating on Iovance Biotherapeutics, Inc. is Buy across 10 analysts, with a mean price target of $14.40 (+3% vs. the current $13.94). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is IOVA's next earnings date?
Iovance Biotherapeutics, Inc. is next scheduled to report earnings around Nov 5, 2026. A full IOVA research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Iovance Biotherapeutics, Inc.?
Analysts covering Iovance Biotherapeutics, Inc. (IOVA) range from a bear-case target of $7.00 to a bull-case high of $20.00, with a mean consensus target of $14.40 across 10 analysts. The spread of $13.00 (93% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Iovance Biotherapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Iovance Biotherapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full IOVA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Iovance Biotherapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.